Halia is a preclinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases.
We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Location: United States, Utah, Salt Lake City
Employees: 11-50
Total raised: $12.22M
Founded date: 2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.12.2022 | - | $12.22M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 31.01.2024 | Halia Therapeutics Inks $30M Series C Financing | LEHI, UT, Halia Therapeutics, a clinical-stage biopharmaceutical company, announced the completion... | vcnewsdail... |
| - | Halia Therapeutics | “At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of pa... | fastfounde... |
| - | Halia Therapeutics | “Discovering and developing novel chronic inflammation therapies to improve the lives of patients wi... | fastfounde... |